GSK Exits Haleon with $1.52 Billion Stake Sale

1. GlaxoSmithKline (GSK) has announced plans to sell its remaining stake in Haleon, the consumer healthcare business it spun off in July 2022.
2. The sale is expected to raise approximately $1.52 billion for GSK, which will be used to strengthen its balance sheet and fund future investments.
3. Haleon was formed as a joint venture between GSK, Pfizer, and Novartis, and was later spun off as an independent company. It includes well-known consumer health brands such as Sensodyne, Panadol, and Centrum.
4. GSK's divestment from Haleon is part of its strategy to focus on its core pharmaceuticals business and invest in research and development.
5. The sale of GSK's remaining stake in Haleon is expected to be completed in the coming months, subject to regulatory approvals and market conditions.
6. GSK's exit from Haleon marks the end of a long-standing partnership between the two companies and signals a new chapter for both businesses.